INSM
Insmed Incorporated
INSM's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over INSM overall, supported by stronger fundamentals and lower modeled downside.
INSM Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Under pressure | |
| Unavailable |
INSM's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
INSM PE Valuation
INSM has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
INSM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect INSM's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
INSM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.83 | +$3.34 |
| Q2 2026 | -$4.12 | +$1.57 |
| Q1 2026 | -$5.76 | +$0.17 |
| Q4 2025 | -$6.42 | -$0.85 |
| Q3 2025 | -$6.17 | -$0.62 |
| Q2 2025 | -$5.69 | -$0.30 |
| Q1 2025 | -$5.93 | -$0.70 |
| Q4 2024 | -$5.57 | -$0.23 |
INSM lost $2.83 per share over the past year, a smaller loss than the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over INSM on earnings quality, reporting a profit while its opponent remains loss making.
INSM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $524.4M | +268% |
| Q2 2026 | $425.5M | +296% |
| Q1 2026 | $306M | +230% |
| Q4 2025 | $263.8M | +153% |
| Q3 2025 | $142.3M | +52% |
| Q2 2025 | $107.4M | +19% |
| Q1 2025 | $92.8M | +23% |
| Q4 2024 | $104.4M | +25% |
INSM has the edge over LLY on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -17% | +240 points |
| Q2 2026 | -0.4% | +291 points |
| Q1 2026 | -50% | +217 points |
| Q4 2025 | -121% | +99 points |
| Q3 2025 | -257% | -29 points |
| Q2 2025 | -291% | +29 points |
| Q1 2025 | -267% | -75 points |
| Q4 2024 | -221% | -7.6 points |
INSM's operating margin was −17% last quarter, up 240 points from the same quarter a year ago, near the top of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over INSM on profitability, with a higher operating margin.
INSM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$42.1M | +$180.1M |
| Q2 2026 | -$95.1M | +$114M |
| Q1 2026 | -$226.2M | +$45.9M |
| Q4 2025 | -$264.2M | -$61.4M |
| Q3 2025 | -$222.2M | -$37.6M |
| Q2 2025 | -$209.1M | -$79.3M |
| Q1 2025 | -$272.2M | -$83.4M |
| Q4 2024 | -$202.8M | -$69.8M |
INSM has burned cash in almost every quarter: −$628M over the past year, against −$906M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over INSM on cash generation, producing positive trailing cash flow while its opponent burns cash.
INSM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +1.4M shares |
| 1 year | +3.3% | +7M shares |
| 3 years | +53% | +75.9M shares |
| 5 years | +87% | +102M shares |
| Available history | +159% | +134M shares |
INSM has 219M diluted shares, up 3.3% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over INSM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
INSM Net Leverage
INSM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
INSM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.8 | Neutral |
| Stochastic | 50.6 | Neutral |
INSM's weekly RSI is 51 (neutral) and its Stochastic is 51 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
INSM PE vs Healthcare Sector
INSM has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
INSM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $108.0 | 9.3% above |
| 20 week MA | $114.0 | 3.6% above |
| 50 week MA | $131.6 | 10% below |
| 100 week MA | $119.3 | 1% below |
| 200 week MA | $78.3 | 51% above |
INSM's trend is mixed: it's above three of its five weekly moving averages, and 51% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over INSM on trend strength, trading above more of its moving averages.
INSM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $23.7 | $35.4 | +49% |
| 2021 | $35.4 | $28.3 | -20% |
| 2022 | $28.3 | $19.4 | -32% |
| 2023 | $19.4 | $31.0 | +60% |
| 2024 | $31.0 | $69.6 | +125% |
| 2025 | $69.6 | $177.9 | +156% |
| 2026 YTD | $177.9 | $118.1 | -34% |
INSM is down 34% so far in 2026, after finishing higher in four of the previous six years.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over INSM on returns for 2026, with the stronger performance.